Peregrine Capital Management’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-342,845
| Closed | -$4.7M | – | 335 |
|
|
2024
Q4 | $4.7M | Buy |
342,845
+36,958
| +12% | +$507K | 0.14% | 229 |
|
|
2024
Q3 | $8.38M | Buy |
305,887
+670
| +0.2% | +$18.4K | 0.25% | 103 |
|
|
2024
Q2 | $7.47M | Buy |
305,217
+3,960
| +1% | +$96.9K | 0.22% | 153 |
|
|
2024
Q1 | $6.42M | Buy |
301,257
+75
| +0% | +$1.6K | 0.18% | 191 |
|
|
2023
Q4 | $5.76M | Buy |
301,182
+20,415
| +7% | +$391K | 0.17% | 211 |
|
|
2023
Q3 | $4.5M | Sell |
280,767
-17,622
| -6% | -$283K | 0.13% | 236 |
|
|
2023
Q2 | $6.92M | Buy |
+298,389
| New | +$6.92M | 0.19% | 221 |
|